BETH ISRAEL DEACONESS MEDICAL CENTER
Personalized Adoptive T-cell Therapy for AML
Personalized Adoptive T-cell Therapy for AML is a funding opportunity from BETH ISRAEL DEACONESS MEDICAL CENTER, up to 728501, closing December 31, 2026.
Dec 31, 2026
(153d left)Overview
Abstract/Project Summary The development of strategies to expand and activate AML specific T cells is of critical importance. We have developed a personalized cancer vaccine in which patient derived tumor cells are fused with autologous dendritic cells (DCs), presenting a broad array of antigens that capture the…